ARTICLE | Discovery & Translation
BioCentury’s roundup of translational innovations
By Danielle Golovin, Senior Biopharma Analyst
March 16, 2024 1:22 AM UTC
MIT and Genentech teams are the latest to point to modulation of specific immunosuppressive cell types as a path to increasing the efficacy of next-generation immuno-oncology agents whose targets have not yet secured clinical proof of concept.
In a Nature Communcations study, the MIT authors showed that depleting or inhibiting regulatory T cells (Tregs) via an anti-CD4 mAb or an anti-CTLA-4 mAb, respectively, increased responses to a 4-1BB agonist mAb fused to the ectodomain of the collagen-binding protein LAIR1, in a syngeneic, poorly immunogenic mouse model of melanoma. The authors proposed that Tregs in tumor-draining lymph nodes dampen the T cell priming required to maximize responses to immune agonists…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651778/boosting-immunotherapy-by-counteracting-tregs-in-tumor-draining-lymph-nodes-and-more